The primitive nervous system begins as a flat neural plate 2 weeks after conception, having arisen from ectoderm. This plate becomes indented by a long itudinal groove at 20 days with neural folds on the flanks. These folds begin to fuse in the midline forming a cylinder in the middle of the plate and then in a zipper fashion this dorsal closure is promulgated rostrally and caudally resulting in a tubular structure with an open anterior and posterior aperture corresponding to the anterior and the posterior neuropore. At 26 days the anterior neuropore closes and at 29 days the posterior. Factors necessary for the neural tube formation are intrinsic in the neural ectoderm and adjacent mesoderm.
A teratological insult in embryogenesis timed to interfere with the closure of the anterior neuropore will result in anencephalus with failed development of the telencephalic vesicle and the normal cerebral hemispheres are replaced by a mass of undifferen tiated cells and abnormal vessels. Anencephalus is responsible for about half of all the neural tube defects and is incompatible with life, and the natural history is for spontaneous abortion, still birth or death shortly after delivery.
Failure of closure of the posterior neuropore results in an exposed spinal cord. When this is subjected to intrinsic hydrodynamic forces and extrinsic mechanical and chemical forces of the intrauterine environment, then progressive destruction of the spinal cord occurs, which results in the full panoply of permanent neurological damage and deformity recognised at birth as spina bifida (myelomeningoceoele). l Although it is predominantly a neuro-ectodermal abnormality there is often involvement of adjacent mesodermal structures. The resultant spina bifid a deficit includes life-long handicap from motor and sensory paraplegia, deformity, neuropathic bladder and bowel, Chiari II malformation and hydrocepha lus etc, with the extent of the deficit depending predominantly on the pattern and level of spinal cord involvement.
Encephalocoeles are traditionally considered as closed neural tube defects but they are probably a Correspondence: Dr RA Minns, PhD, FRCP (Ed) post neurulation defect and their precise pathogenesis has yet to be clarified. 2 They result in failure of fusion of the midline cranial structures with herniation of brain tissue and cerebro-spinal fluid. They are a distinct group of neural tube abnormalities with many more females than males represented, differ ences in the anterior versus posterior site depending upon race, ie anterior encephalocoeles frequent among Bantus and Thais, and they are associated with a number of characteristic genetic conditions such as the autosomal recessive Meckel-Gruber syndrome, auto somal recessive occipital encephalocoele with myopia and retinal dysplasia, 3 Joubert syndrome, Walker syndrome etc. They have been reported in association with forty miscellaneous conditions. They may even be deformations rather than malformations arising by extracranial evagination of brain tissue at 20 weeks following raised ventricular pressure in foetal hydro cephalus. 4 Encephalocoeles result in hydrocephalus, mental retardation with or without microcephaly, epilepsy and ataxia from associated dysplasia in the occipital lobe, cerebellum and cerebral cortex.
In broad terms therefore, neural tube defects result from incomplete neurulation and refer to a wide spectrum of congenital malformations in which separation of the midline vertebral and cranial elements are the common feature, but are usually taken to mean anencephalus, spina bifida and encephalocoeles.
Aetiology of neural tube defects
It has long been accepted that there was a genetic environmental interaction in the causation of neural tube defects. In any large series a positive family history is obtained in about 10% and we have seen family trees with n e ural tube defects extending through five generations. If a man or woman with an affected offspring, or either they themselves suffer from the condition, their risk of having a child with neural tube defect is increased tenfold (about 5% risk). After two such affected pregnancies it is increased 20 times (10-15%). The risk can therefore be calculated knowing a detailed family history. These genetic and other epidemiological studies have given rise to the concept of high risk 'patients': (1) those with a past history of neural tube defect; (2) maternal age of < 20 or > 35 years; (3) parity (primip or grand multip); (4) social class (poverty).
There are 13 genetic loci in rodent models at which mutations are known and three mouse chromosomal models that produce neural tube defects. 5 In man various chromosome abnormalities, Trisomy 13 and 18 and triploidy and other unbalanced chromosome rearrangements and ring chromosomes, are known to be causes of neural tube defects. Single gene autosomal recessive conditions such as Walker-Warburg, Jarco Levin, Meckel-Gruber, and Robert syndromes are associated with neural tube defects. Autosomal dominant conditions have an association also, such as median facial cleft and the syndrome of anterior sacral meningocoele and anal stenosis.
As well as the genetic risk it has long been known that teratogens are capable of inducing neural tube defects in humans and experimental animals. Copp et al5 discovered from the medical literature more than 60 teratogens that produce neural tube defects in animals, including radiation, maternal hyperthermia, diabetes mellitus, hyper-or hypovitaminosis A, infections such as congenital rubella, toxoplasmosis, cytomegalovirus, and drugs such as aminopterin, valproic acid, aliphatic nitriles, trypan blue, cyclophosphamide and cyanide. A number of environmental hazards have been hypothe sised, particularly dietary agents such as soft water, blighted potatoes, nitrate cured corned beef, canned peas treated with magnesium salts, effluent from factories and zinc deficiency.
Periconceptional folate studies
Hibbard in 1964 6 first suspected that folic acid (a vitamin of the B group) might be involved in the aetiology of neural tube defects, and following this two intervention studies were published which involved vitamin supplementation around the time of concep tion for women who had already had a child with a neural tube defect. 7 , 8 The first study was not randomised and women were given a mixture of eight vitamins including 0.36 mg per day of folic acid. The risk of recurrence in this supplemented group was about one-seventh that of the un supplemented group. In the second study, which was a small randomised trial of 4 mg per day of folic acid, a significant lower recurrence rate was noted. In a further six observational studies and a non-randomised supplementation study, all with the exception of one showed an association but these studies all either suffered from bias, or were non randomised, or were inconclusive. 9 -IS To avoid bias, a large MRC study was proposed and launched in July 1983 with the intention of obtaining at least 2000 pregnancies. 16 This was an international multicentre double-blind randomised trial involving 33 centres, half in the UK. Women with a previous neural tube defect, not associated with one of the autosomal recessive conditions, who were Folic acid and neural tube defects RA Minns planning another pregnancy and not already taking supplements, and did not suffer from epilepsy, were included. The effect of supplementation was investi gated by a factorial study design which ensured that three-quarters of those taking part received folate or multi-vitamins, or both, with women randomly allocated to one of four supplementation groups: (1) folic acid alone; (2) other vitamins alone (vitamin A, thiamin, riboflavin, B6, vitamin C, vitamin D); (3) both; (4) neither. By April 1991 sufficiently conclusive results were obtained using sequential analysis to warrant stopping the trial. There had been 1195 completed pregnancies with a known outcome. Twenty-seven had a known neural tube defect, six in the folic acid groups and 21 in the other two groups, meaning a 72% protective effect. It was also concluded that the other vitamins showed no protective effect for neural tube defect, nor did supplementation cause any harm. This careful study assessed compliance and took precautions, by measuring serum folic acid, that women did not additionally supplement themselves. It must be recognised that supplementation with 4 mg per day of folic acid did not prevent all the neural tube defects and these cases did not have unusually low serum folic acid concentrations, and this probably reflects the heterogeneous nature of the condition.
The second significant study from Hungary was a randomised controlled trial, that showed that the occurrence of neural tube defects could be appreci ably reduced by giving periconceptional multivitamin supplements which included 0.8 mg of folic acid. 17 This study was extended to look at the effect on other congenital abnormalities as well, again with a randomised control trial of supplementation with multivitamins (including 0.8 mg of folic acid), or trace elements supplements daily for at least 1 month before conception and at least 2 months after conception. 18 It was found that periconceptional multivitamin supplements could reduce not only the rate of neural tube defects but the rate of other major genetic syndromic congenital abnormalities such as conotruncal cardiovascular anomalies, defects of the urinary tract, congenital hypertrophic pyloric stenosis, and congenital limb deficiences.
Mechanism of action of folic acid
The mechanism is still being investigated but several positive facts are emerging. Firstly, it seems unlikely that there is a primary folate deficiency. Kirk et aI have shown that mothers carrying foetuses with neural tu be defects have a lower Bl2/folate during pregnancy than mothers carrying normal foetuses, and both folate and Bl2 are independently predictive of neural t u b e defects with Bl2/folate levels well above the deficiency range, suggesting a metabolic block rather than a simple deficiency state.
19 There is other evidence that B12 is also involved and others have found an elevated homocysteine level significantly higher for mothers of neural tube defect patients during pregnancy than B12 matched controls, especially in the lower half of the B 12 distribution, ie these cases metabolise homocys teine less well than controls at comparable levels of BI2/folate. 2o , 21 Adams et al also reported elevated methylmalonic acid values in mothers whose children had neural tube defects, a further marker of B 12 insufficiency. 22 Of the 16 f 0 la te dependent enzyme systems, methionine synthase is the only one which requires B 12 as well as folate, and a defect in methionine synthase would lead to this increased level of homocysteine suggesting an abnormality of methio nine synthase together with its co-factor Bl2 could be the responsible metabolic defect. 2 0
Other situations that can result in an increased homocysteine level might also be implicated and a mutation has been identified (677 C� T mutation) in the 5,1 O-methylenetetrahydrofolate reductase (MTHFR) gene on chromosome I p 36.3, which is present in 13% of neural tube defect patients, 16% of mothers, and 10% of fathers, compared to 5% of controls who are homozygous for this. 23 This mutation results in a decreased MTHFR activity, a low plasma folate (another marker of abnormal methionine synthase activity) and high levels of homocysteine. This mutation can be regarded as a genetic risk factor for spina bifida and supports the hypothesis of defective folate metabolism in at least a subset of mothers with neural tube defects. 24 Cystathionine synthesase abnormalities can also raise homocysteine and this has also been reported in a minority of patients with neural tube defects. 25 Overcoming an abnormality in homocysteine metabo lism, particularly an abnormality of methionine synthase by folic acid supplementation, is presently the favoured postulated mechanism of action of folic acid. Methionine synthase is pivotal in methylation reactions for producing myelin basic protein and in making tetrahydrofolate for DNA synthesis, either of which may be the responsible pathway for producing neural tube defects. 26 In experimental animals various results have been found, for example in mice folate did not prevent neural tube defects but methionine did. 27 The folic acid antagonists aminopterin and methotrexate did not cause neural tube defects but rather limb deficiencies. Valproic acid results in 1 -2 % incidence of spina bifida possibly by interacting with embryonic folate metabolism. 28 The 'curly tail mouse' has been studied extensively to determine agents which prevent neural defects in embryos and prevention has been found with retinoic acid, inositol, hydroxyurea, mitomycin C, 5-flurouracil, cytosine arabinoside, possibly riboflavin, vitamin C, vitamin D2. But no prevention was seen with folic acid, folinic acid, pregnavite forte F, B6, B12, triamcinolone, cyclohex amide, zinc, homocysteine, methionine and thymi dine. 29 Ovulatory drugs such as chlomiphene and hormones do not cause an increased risk of neural tube defect. 3 0
Optimal delivery method of folic acid
Conclusive evidence from the MRC and Hungarian studies means that prevention is effective for women who have not had a foetus with a neural tube defect as well as for those who have, 31 and a clear policy is necessary to prevent primary occurrences and recur rences. This could be accomplished by either supple mentation or food fortification, and because of the public health implications of the latter option the advantages and disadvantages of each are discussed.
Supp lementation has been recommended by the Expert Advisory Group to prevent recurrences of neural tube defects by taking a daily dose of 4 mg before conception and continued until the 12th week of pregnancy. 32 This advice was also for the offspring of women or men with spina bifida. Only 5 mg tablets are available and these only on prescription. To prevent the first occurrence of a neural tube defect extra folate was recommended for all women prior to conception and during the first 12 weeks of pregnancy, and the suggested ways of achieving this were by extra intake of folate rich foods such as green leafy vegetables, not over cooking, and by eating foods fortified with folic acid, and additionally taking a food supplement. The recommended supplemental dose to prevent occurrences was 0.4 mg of folic acid daily when they begin trying to conceive or on the suspicion of pregnancy, or if the women recognises the possibility of pregnancy following unprotected sexual intercourse until the 12th week of pregnancy. In any case at the suspicion of pregnancy supplementation should commence at once. 0.4 mg tablets are available without prescription from chemists or health food stores.
The advantages of supplementation are that it targets only the population who are at risk and as such the type of medication, its dose and the target group can be clearly defined.
The disadvantages of supplementation are: (1) That a large percentage of pregnancies are unplanned and this includes about 95% of the pregnancies that end in a neural tube defect. (2) The practical difficulties are considerable in attempting to give all women supplementation before falling pregnant, particularly those in a low socio-economic group who are at a higher risk. (3) There must be a public health strategy in conjuction with the supplementation about the necessity of it, dietary advice etc. (4) Although small, there is still a financial price to pay for the supplement. (5) The theoretical and unknown risks of providing supplementation to popUlations who already have a low incidence of neural tube defects. (6) The background dietary folic acid being con sumed before supplementation will be variable and thus the total daily intake variable. (7) The advantages of fo rtification are:
(1) It ensures compliance in all of the population at risk by consumption by the whole population.
(2) Collective action has always been an essential part of public health achievements. Secondary prevention through screening with the option of termination has been available for the last 20 years. All cases of anencephaly and 66% of cases of spina bifida will be identified by alphafetoprotein (blood and aminiotic) and ultrasound scan. Termina tion together with a selective policy postnatally has been responsible for the main decline in prevalence. Primary preventative measures therefore in preventing the development of neural tube defect in the embryo by periconceptional vitamins would have an additional and overlapping contribution to the decline.
The birth prevalence of myelomeningocoele and encephalocoeles admitted to a regional paediatric neurology service in Edinburgh over a 30 year period from 1965 -1994 showed the dramatic impact of antenatal screening from 1975 with a steady decline to about 1985. The virtually static nature of our birth prevalence since then is largely due to the continued effectiveness of screening and termination, and it must be remembered that there will always be a limit to the effectiveness of antenatal screening/termination because not all pregnant women avail themselves of all antenatal services. The impact of periconceptional vitamins supplementation is too early to say, but there does appear to be a decline in the total prevalence, ie live births plus terminations and stillbirths using ICD-9 statistics. For the Lothian Region in 1985 the total prevalence of neural tube defects was 22, and since 1993 has been less than 10. In the UK approximately 2000 would still occur although three-quarters end in stillbirth or termination and most of these would be prevented by fortification.
Prior to the periconceptional vitamin study the alternatives were for screening and termination (depending on parental wishes) of all AFP positive foetuses or those detected by ultrasound. There is no possibility of predicting in utero the degree of neurological deficit and Hunt with a series of 117 spina bifid a adolescents between 16 and 20 years of age, who were likely to have had an elevated AFP level, showed that some 7% of these had little or no disability. 41 The AFP and ultrasound are not discriminating and if positive all are offered termina tion. The 'verebral level' and the 'lesion level' and the degree of hydrocephalus from the ultrasound are not good indicators of subsequent handicap and vice versa. Low level lesions may have a very significant handi cap. What the ultrasound cannot do is detect the motor or sensory neurological level, although attempts have been made to deduce levels from flexion and extension of the knee. Since it is not possible to detect the severity of neurological damage in-utero a termination policy is an imprecise secondary preven tion of neural tube defects so that all lesions functionally good or bad with an elevated AFP are offered termination.
Postnatally many units have used a selective policy based on modified Lorber criteria for operation or not. 42 It must be remembered that the operation is not curative and, our own unit has a selective postnatal policy but with the caveat that a U-turn in management policy is practised if the child survives.
Secondary prevention (termination of affected foetuses regardless of severity, together with postnatal 'selecting out') is ethically less acceptable than primary prevention of the neural tube defect, together with the possibility that in the future, in-utero repair of the open spina bifid a may be feasible for those neural tube defects not prevented by periconceptional vitamins. I A number of unanswered questions remain. For example the dosage, at present a 5 mg tablet, is made by a number of manufacturers, it is cheap and there is unlikely to be pressure to develop a 4 mg tablet for daily consumption, but could it be that the original 0.36 mg is enough or 0.8 mg as suggested in the Hungarian study. Neither is it known how long before conception this is required and will dietary and supplementary folic acids be compatible, and will the benefits of folic acid be the same in populations with a previously low prevalence.
Periconceptional folic acid supplementation and fortification represents a major advance in the prevention of neural tube defects in a primary preventative way. The MRC trial which brought this about is a milestone which, with or without termination, will make a very dramatic influence on the number of infants likely to be born with this major congenital malformation.
